Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.72 |
| ▸ | BCHE | P06276 | 4/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | HTR1D | P28221 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | HTR1F | P30939 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4073800 | 0.99 | HTR6 (0.71) | HTR6BCHEHTR1AHTR1DHTR1B | |
| SCHEMBL5243945 | 0.94 | HTR6 (0.71) | HTR6BCHEHTR1AHTR1DHTR1B | |
| SCHEMBL4073506 | 0.87 | HTR6 (0.72) | HTR6BCHE | |
| SCHEMBL3320088 | 0.84 | HTR6 (0.83) | HTR6BCHEHTR1AHTR1DHTR1B | |
| SCHEMBL5243027 | 0.84 | HTR6 (1.00) | HTR6BCHE | |
| SCHEMBL17927509 | 0.83 | HTR6 (0.71) | HTR6BCHE | |
| Hydrochloric Acid SCHEMBL5242032 | 0.83 | HTR6 (0.98) | HTR6BCHE | |
| Hydrochloric Acid SCHEMBL5757469 | 0.83 | HTR6 (0.81) | HTR6BCHEHTR1AHTR1DHTR1B | |
| SCHEMBL5242307 | 0.82 | HTR6 (0.65) | HTR6BCHEHTR1AHTR7DRD3 | |
| SCHEMBL13710948 | 0.82 | HTR6 (0.65) | HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353904-B9 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1353904-B1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | claimed |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | claimed |
| US-6710069-B2 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-03-23 | — | — | US | claimed |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-07 | — | — | US | claimed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7271180-B2 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | disclosed |
| US-6710069-B2 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-03-23 | — | — | US | disclosed |
| EP-1353904-A1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-6509357-B1 | Use there of for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the | WYETH | 2003-01-21 | — | — | US | disclosed |
| WO-2002059088-A1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR1B, HTR1A | HTR6 1/4885BCHE 2315/4885HTR1A 3/4885 |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885BCHE 2412/4885HTR1A 3/4885 |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885BCHE 2412/4885HTR1A 3/4885 |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | HTR6, HTR1B, HTR3B | HTR6 1/4885BCHE 1688/4885HTR1A 4/4885 |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885BCHE 2412/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.